Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Why Biogen Stock Sank While the Market Soared on Thursday
07:59pm, Tuesday, 31'st Mar 2026
If all goes as planned, it'll soon be the owner of Apellis Pharmaceuticals. The company's asset-to-be has two commercialized medicines on the market based on the same active ingredient.
Biogen Agrees $5.6B Apellis Deal as Shares Surge 136% on Announcement
04:11pm, Tuesday, 31'st Mar 2026
Biogen (BIIB) is moving decisively to reposition its growth profile, agreeing to acquire Apellis Pharmaceuticals (APLS) for $5.6 billion in a deal that could pr
Biogen Inc. (BIIB) Discusses Proposed Acquisition of Apellis and Strategic Growth Objectives Transcript
03:52pm, Tuesday, 31'st Mar 2026
Biogen Inc. (BIIB) Discusses Proposed Acquisition of Apellis and Strategic Growth Objectives Transcript
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio
12:22pm, Tuesday, 31'st Mar 2026
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) will acquire Apellis Pharmaceuticals Inc (NASDAQ:APLS) for $41 per share in cash, in a deal valued at approximately $5.6 billion, it was announced on Tuesday. Apel
Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza
12:00pm, Tuesday, 31'st Mar 2026
BIIB gains after the FDA clears higher-dose Spinraza, with data showing improved motor function and potential to counter rising SMA competition.
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio
08:20am, Tuesday, 31'st Mar 2026
Biogen Inc (NASDAQ:BIIB, XETRA:IDP) will acquire Apellis Pharmaceuticals Inc (NASDAQ:APLS) for $41 per share in cash, in a deal valued at approximately $5.6...
Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases
08:07am, Tuesday, 31'st Mar 2026
Biogen, already developing a drug that can be used to treat several kidney disorders, is paying a large premium for Apellis Pharmaceuticals
Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion
07:44am, Tuesday, 31'st Mar 2026
Biogen agreed to acquire Apellis Pharmaceuticals for approximately $5.6 billion, expanding its portfolio in immunology and rare-disease medicines.
Biogen to buy Apellis Pharmaceuticals for $5.6 billion
07:05am, Tuesday, 31'st Mar 2026
Biogen said on Tuesday it has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash.
CAMBRIDGE, Mass. and WALTHAM, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced the companies have entered into a de
Biogen Stock Pops After FDA Approves New High-Dose Spinraza For Spinal Muscular Atrophy
01:40pm, Monday, 30'th Mar 2026
• Biogen stock is moving in positive territory. Why is BIIB stock advancing?
Biogen high-dose Spinraza approval seen supporting long-term growth
12:12pm, Monday, 30'th Mar 2026
The US Food and Drug Administration has approved a higher-dose version of Spinraza, a key therapy from Biogen Inc (NASDAQ:BIIB, XETRA:IDP) for spinal muscular atrophy (SMA), a move analysts at Jefferi
Biogen high-dose Spinraza approval seen supporting long-term growth
08:11am, Monday, 30'th Mar 2026
The US Food and Drug Administration has approved a higher-dose version of Spinraza, a key therapy from Biogen Inc (NASDAQ:BIIB, XETRA:IDP) for spinal...
US FDA approves higher-dose of Biogen's genetic disorder drug
07:36am, Monday, 30'th Mar 2026
The U.S. Food and Drug Administration has approved a higher-dose version of Biogen's drug for a rare genetic disorder that causes progressive muscle weakness, offering
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
07:30am, Monday, 30'th Mar 2026
The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA patie
